参考资料：

[1]Efficacy and toxicity for CD7 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory T-cell lymphoma. EBMT 2023 P178

[2]DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL. EHA 2023 P1168

[3]EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA. EHA 2023 P1173

[4]A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA. EHA 2023 P1195

[5]CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL. EHA 2023 PB2333

[6]CAR T-Cell Therapy Provides an Opportunity for Further Consolidation Treatment for Relapsed or Refractory Adult Burkitt Lymphoma Patients. ASH 2023 P1746

[7]Efficacy and Safety of Autologous Stem Cell Transplantation Combined with Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Refractory/Relapsed B-Cell Lymphoma. ASH 2023 P3434

[8]A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter’s Transformation. ASH 2023 P4638

[9]The Mini-Teddi-R Treatment Demonstrated a High Rate of Remission in Patients with DLBCL Involving the CNS Who Had Previously Been Exposed to BTK Inhibitors. ASH 2023 P4507

[10]A PROSPECTIVE INVESTIGATION INTO THE TIMING AND STATUS OF BCMA-CART IN SECONDARY PLASMA CELL LEUKEMIA. EHA 2023 PB2101

[11]Chen, W., Shi, H., Liu, Z., Yang, F., Liu, J., Zhang, L., Wu, Y., Xia, Y., Ou, Y., Li, R., Zhang, T., Zhang, J., Ke, X., Hu, K., & Yu, J. (2023). Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(8), 1484–1495. https://doi.org/10.1158/1078-0432.CCR-22-2924

[12]Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies. ASH 2023 P3513

[13]Assessment of Activities of Daily Living(ADL) Scale can be Used to Predict overall Survival after CAR-T cell Therapy in Elderly People(over 70 Years of Age) with Refractory/Relapsed B-Cell Lymphoma. ASH 2023